Skip to content
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases

Press Releases

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect

May 17, 2023
Read More »

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

January 9, 2023
Read More »

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

December 5, 2022
Read More »

Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase

October 10, 2022
Read More »

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium

September 15, 2022
Read More »

Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022

August 26, 2022
Read More »
Page1 Page2 Page3 Page4 Page5
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
CONTACT

Privacy Policy      Terms of Use

2025 © Imbria Pharmaceuticals​

Linkedin